Cancer Center, Mie University Hospital, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
BMC Cancer. 2020 Jun 29;20(1):606. doi: 10.1186/s12885-020-07098-4.
Cancer testis (CT) antigens are promising targets for cancer immunotherapies such as cancer vaccines and genetically modified adoptive T cell therapy. In this study, we evaluated the expression of three CT antigens, melanoma-associated antigen A4 (MAGE-A4), New York oesophageal squamous cell carcinoma 1 (NY-ESO-1) and sarcoma antigen gene (SAGE).
MAGE-A4, NY-ESO-1 and/or SAGE antigen expression in tumour samples was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). Informed consent was obtained from individuals prior to study enrolment.
In total, 585 samples in 21 tumour types were evaluated between June 2009 and March 2018. The positive expression rates of these CT antigens were as follows: MAGE-A4, 34.6% (range, 30.7-38.7); NY-ESO-1, 21.0% (range, 17.2-25.1); and SAGE, 21.8% (range, 18.5-25.4). The MAGE-A4 antigen was expressed in 54.9% of oesophageal cancers, 37.5% of head and neck cancers, 35.0% of gastric cancers and 34.2% of ovarian cancers; the NY-ESO-1 antigen was expressed in 28.6% of lung cancers, 25.3% of oesophageal cancers and 22.6% of ovarian cancers; and the SAGE antigen was expressed in 35.3% of prostate cancers, 32.9% of oesophageal cancers and 26.3% of ovarian cancers. The most common tumour type in this study was oesophageal cancer. MAGE-A4, NY-ESO-1 and SAGE antigen expression were assessed in 214 oesophageal cancer samples, among which 24 (11.2%) were triple-positive, 58 (27.1%) were positive for any two, 59 (27.6%) were positive for any one, and 73 (34.1%) were triple negative.
Oesophageal cancer exhibited a relatively high rate of CT antigen mRNA expression positivity.
癌症睾丸抗原（CT）是癌症免疫疗法的有前途的靶点，例如癌症疫苗和基因修饰的过继性 T 细胞疗法。在这项研究中，我们评估了三种 CT 抗原，黑色素瘤相关抗原 A4（MAGE-A4）、纽约食管鳞状细胞癌 1（NY-ESO-1）和肉瘤抗原基因（SAGE）的表达。
通过定量实时聚合酶链反应（qRT-PCR）评估肿瘤样本中 MAGE-A4、NY-ESO-1 和/或 SAGE 抗原的表达。在研究入组前获得了个人的知情同意。
在 2009 年 6 月至 2018 年 3 月期间，共评估了 21 种肿瘤类型的 585 个样本。这些 CT 抗原的阳性表达率如下：MAGE-A4，34.6%（范围，30.7-38.7）；NY-ESO-1，21.0%（范围，17.2-25.1）；和 SAGE，21.8%（范围，18.5-25.4）。MAGE-A4 抗原在 54.9%的食管癌、37.5%的头颈部癌、35.0%的胃癌和 34.2%的卵巢癌中表达；NY-ESO-1 抗原在 28.6%的肺癌、25.3%的食管癌和 22.6%的卵巢癌中表达；SAGE 抗原在 35.3%的前列腺癌、32.9%的食管癌和 26.3%的卵巢癌中表达。本研究中最常见的肿瘤类型是食管癌。在 214 例食管癌样本中评估了 MAGE-A4、NY-ESO-1 和 SAGE 抗原的表达，其中 24 例（11.2%）为三阳性，58 例（27.1%）为双阳性，59 例（27.6%）为单阳性，73 例（34.1%）为三阴性。
食管癌 CT 抗原 mRNA 表达阳性率相对较高。
